Document is current
Any future updates will be listed below
-
Authors
Zhou, Yitian https://orcid.org/0000-0003-3066-5444
Lauschke, Volker M. https://orcid.org/0000-0002-1140-6204
-
Funding
Funding for this research was provided by:
Vetenskapsrådet (2019-01837, 2021-02801)
- License Information
-
More Information
Article History
Received: 5 April 2022
Revised: 5 August 2022
Accepted: 19 August 2022
First Online: 6 September 2022
Competing interests
: YZ and VML are co-founders and shareholders of PersoMedix AB. In addition, VML is CEO and shareholder of HepaPredict AB and discloses consultancy work for Enginzyme AB.
